摘要:
The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
摘要:
Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.
摘要:
The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
摘要:
Diaromatic compounds, characterised in that they correspond to the following general formula: ##STR1## in which: R.sub.1 is --CH.sub.3, --CH.sub.2 OH, --COR.sub.8 or --CH.sub.2 OCOR.sub.9, R.sub.8 is H, OH, --OR.sub.10, --N(rr') or alkyl, R.sub.10 is alkyl, alkenyl, aryl or aralkyl, r and r' being H, alkyl, aryl, aralkyl, etc., r and r' together form a heterocycle, R.sub.9 is alkyl, alkenyl or a sugar residue, R.sub.2 and R.sub.3 are --OR.sub.11 or --OCOR.sub.11, R.sub.11 is H, alkyl, fluoroalkyl, aryl or aralkyl, R.sub.3 in addition being H, R.sub.4 is H, OH, alkyl, alkoxy, F, Cl or --CF.sub.3, R.sub.5 and R.sub.7 are H, OH, alkoxy, .alpha.-substituted alkyl or .alpha.,.alpha.'-disubstituted alkyl, etc., R.sub.6 is H, OH, alkyl, alkoxy, cycloalkyl, etc., R.sub.5 and R.sub.7 cannot simultaneously be OH or alkoxy and R.sub.4, R.sub.5, R.sub.6 and R.sub.7 cannot simultaneously be H, R.sub.5 and R.sub.6 or R.sub.6 and R.sub.7 can form, with the aromatic ring, a ring with 5 or 6 members, X is chosen from amongst:(i) --C(R.sub.13 R.sub.14)--C(R.sub.16 R.sub.18)--W--, (ii) --C(R.sub.14)--W--R.sub.16 C(R.sub.18 R.sub.19)--, (iii) --C(R.sub.13 R.sub.14)--C(R.sub.15 R.sub.16)--C(R.sub.18 R.sub.20)--, (iv) --CR.sub.17 .dbd.CR.sub.21 --C(R.sub.13 R.sub.14)--in which:W is O, --NR.sub.12 or S(O).sub.n, n=0, 1 or 2, R.sub.13, R.sub.15 and R.sub.20 are H, --OR.sub.11, --OCOR.sub.11 etc., R.sub.14, R.sub.16, R.sub.18 and R.sub.19 are H, aralkyl, alkyl, etc., when X is (i) R.sub.13 and R.sub.14 can form .dbd.N--OR.sub.11 or .dbd.N--OCOR.sub.11, when X is (iii) or (iv), R.sub.14, R.sub.16 and R.sub.18 are also --OR.sub.11 or --OCOR.sub.11, or R.sub.13, R.sub.14 or R.sub.15, R.sub.16 taken together can form .dbd.NOR.sub.11 or .dbd.N--OCOR.sub.11, R.sub.12 is H, alkyl, aralkyl, alkenyl, alkynyl or fluoroalkyl, R.sub.17 is H, hydroxyl, alkyl or alkoxy, R.sub.21 is H or alkyl, and the salts of the compounds of formula (I).
摘要:
New polysubstituted derivatives of naphtalene.These derivatives correspond to the following formula: ##STR1## in which: R.sub.1 to R.sub.4 is H or CH.sub.3R.sub.5 is(i) ##STR2## (ii) --C.tbd.N (iii) ##STR3## or (iv) the radical: 2-oxazolinylm is 0 or 1R.sub.8 is H, alkyl, OR.sub.11, R.sub.11 being H, alkyl or ##STR4## R.sub.13 being alkyl or aryl or R.sub.8 is ##STR5## when m=1, r' and r" representing H, alkyl mono or polyhydroxyalkyl, aryl or a heterocycle when they are taken together, R.sub.9 is H or alkyl, R.sub.10 is H, alkyl and the acetals of the said compounds, ##STR6## --OR.sub.14, R.sub.14 being H, alkyl, mono or polyhydroxyalkyl, aryl or aralkyl a rest of a sugar or represents ##STR7## being 0, 1, 2, or 3 R.sub.6 represents a hydrogen atom or a lower alkyl radical,R.sub.7 represents H, alkyl, halogen, hydroxyl, sulfydryl, alkoxy, alkylthio, acyloxy, acylthio, acylamino or primary, secondary or tertiary amino and the salts of the said compounds. These compounds find an application in the cosmetic and pharmaceutical fields.
摘要翻译:萘的新型多取代衍生物。 这些衍生物对应于下式:其中:R 1至R 4为H或CH 3 R 5为(ⅰ)<>)))N(((((((((((the the the the the the the the 基团:2-恶唑啉基m是0或1,R 8是H,烷基,OR 11,R 11是H,烷基或R 13是烷基或芳基,或者R 8是当m = 1时,r'和r“表示 H,烷基单或多羟基烷基,芳基或杂环,当它们一起时,R 9是H或烷基,R 10是H,烷基和所述化合物的缩醛,-OR14,R14是H,烷基,单或 多羟基烷基,芳基或芳烷基,其余的糖或代表0,1,2或3,R 6表示氢原子或低级烷基,R 7表示H,烷基,卤素,羟基,巯基,烷氧基,烷硫基 酰氧基,酰硫基,酰氨基或伯,仲或叔氨基和所述化合物的盐。 这些化合物在化妆品和药物领域中得到应用。
摘要:
Bicyclic aromatic compounds, having the following formula: ##STR1## in which: n=0 or 1;R' represents H, OH, C.sub.1 -C.sub.4 alkoxy or C.sub.1 -C.sub.4 acyloxy;R" represents H or C.sub.1 -C.sub.4 alkoxy;or R' and R" taken together form an oxo (.dbd.O), methano (.dbd.CH.sub.2) or hydroximino (.dbd.N--OH) radical;R represents --CH.sub.2 OH or --COR.sub.7 ;R.sub.7 represents H, OR.sub.8, or ##STR2## R.sub.8 represents H, C.sub.1 -C.sub.4 alkyl, monohydroxyalkyl, polyhydroxyalkyl, aryl or aralkyl, optionally substituted, a sugar residue or ##STR3## where p is 1, 2 or 3 and r' and r" represent H, lower alkyl, monohydroxyalkyl, optionally interrupted by a heteroatom, polyhydroxyalkyl, optionally substituted aryl or benzyl, an amino acid residue or an aminated sugar residue or taken together with the nitrogen atom to which they are attached form a heterocycle;A represents methylene or dimethylene, substituted or not with lower alkyl,R.sub.1, R.sub.2, R.sub.3 and R.sub.4 represent H or lower alkyl,R.sub.1 and R.sub.3 taken together are capable of forming a methylene or dimethylene radical, when A represents dimethylene;R.sub.5 and R.sub.6 represent H or methyl,and the salts of said compounds, as well as their optical and geometric isomers.This active compound is employed in pharmaceutical or cosmetic preparations.
摘要:
PLEIADENES SUBSTITUTED AT THE 7-POSITION, E.G. 1,2,3,7TETRAHYDRO-7-(1-METHYL-4-PIPERIDYL)PLEIADENE AND 1,2,3, 7,12,12A-HEXAHYDRO-7-(1 - METHYL-4-PIPERIDYL)PLEIADEN-7OL, AND DIBENZOHEPTALENES SUBSTITUTED AT THE 8-POSITION, E.G. 1,2,3,4-TETRAHYDRO-8 - (1-METHYL-4-PIPERIDYL)-8H-DIBENZO(B,EF)HEPTALENE, PREPARED FROM A CORRESPONDING KETONE AND GRIGNARD REAGENT, ARE USEFUL AS CENTRAL NERVOUS SYSTEM STIMULTANTS.
摘要:
Pleiadenes substituted at the 7-position, e.g. 1,2,3,7tetrahydro-7(1-methyl-4-piperidyl)pleiadene and 1,2,3,7,12,12a hexahydro-7-(1-methyl-4-piperidyl)pleiaden-7-ol, and dibenzoheptalenes substituted at the 8-position, e.g. 1,2,3,4tetrahydro-8-(1-methyl-4-piperidyl)-8H-dibenzo(b,ef)heptalene, prepared from a corresponding ketone and Grignard reagent, are useful as anti-convulsants.
摘要:
A method for chemical separation of cannabinoids includes: (i) providing a starting organic solvent solution that contains a mixture of cannabinoid acids, (ii) using an aqueous basic solution to remove a portion of the cannabinoid acids from the mixture of cannabinoid acids in the starting organic solvent solution by converting the portion of the cannabinoid acids to cannabinoid carboxylate salts that solubilize in the an aqueous basic solution, (iii) separating the aqueous basic solution in (ii) from the starting organic solvent, (iv) combining the aqueous solution from (iii) with new organic solvent to produce a combined solution, (v) acidifying the combined solution to extract the cannabinoid acids from the aqueous solution to the organic solvent, (vi) separating the organic solvent of (v) from the aqueous solution, and (vii) evaporating the organic solvent of (vi) to leave product cannabinoid acids.